ADMA Biologics Inc Profit Margin 2013-2021 | ADMA
Current and historical gross margin, operating margin and net profit margin for ADMA Biologics Inc (ADMA) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. ADMA Biologics Inc net profit margin as of September 30, 2021 is -108.6%.
|ADMA Biologics Inc Annual Profit Margins
|ADMA Biologics Inc Quarterly Profit Margins
||Medical - Biomedical and Genetics
ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.